<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272103</url>
  </required_header>
  <id_info>
    <org_study_id>KD20003</org_study_id>
    <nct_id>NCT00272103</nct_id>
  </id_info>
  <brief_title>Itopride in Functional Dyspepsia:a Dose Finding Study</brief_title>
  <official_title>A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Dose Finding Study in 4 Parallel Groups to Establish the Efficacy and Safety of an Eight Week Treatment With Itopride Three Times Daily Compared to Placebo in Patients Suffering From Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Adelaide Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Knoll Pharmaceuticals, Germany (now Abbott)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Adelaide Hospital</source>
  <brief_summary>
    <textblock>
      This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the
      treatment of patients with functional dyspepsia.

      The study will test in patients with functional dyspepsia the hypothesis that itopride is
      superior to placebo with regard to the improvement of symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of patients with functional dyspepsia remains unsatisfactory. We will assess the
      efficacy of Itopride, a D2 antagonist with acetylcholinesterase effects in patients with
      functional dyspepsia.

      Patients with functional dyspepsia will be randomized to Itopride (50, 100 or 200 mg tid) or
      placebo. After 8 weeks of treatment, three primary efficacy endpoints will be analyzed: a)
      change of the severity of functional dyspepsia symptoms (assessed by the Leeds Dyspepsia
      Questionnaire), b) patient’s global assessment of efficacy (proportion of patients
      symptom-free or markedly improved)and c) improvement of pain and/or fullness by at least one
      grade on a 5-grade scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date>January 2002</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>After 8 weeks of treatment:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the severity of functional dyspepsia symptoms assessed by the Leeds Dyspepsia Questionnaire)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient’s global assessment of efficacy (proportion of patients symptom-free or markedly improved)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of pain and/or fullness by at least one grade on a 5-grade scale.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Functional Dyspepsia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of functional dyspepsia (Rome criteria) -

        Exclusion Criteria:

        structural or biochemical abnormalities explaining the symptoms, concomitant symptoms of
        gastroesophageal reflux disease or irritable bowel syndrome dominating the clinical picture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald J Holtmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Adelaide Hospital, University of Adelaide</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006 Feb 23;354(8):832-40. Erratum in: N Engl J Med. 2006 Jul 27;355(4):429.</citation>
    <PMID>16495395</PMID>
  </results_reference>
  <verification_date>November 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2006</study_first_submitted>
  <study_first_submitted_qc>January 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2006</study_first_posted>
  <last_update_submitted>May 3, 2006</last_update_submitted>
  <last_update_submitted_qc>May 3, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2006</last_update_posted>
  <keyword>functional dyspepsia</keyword>
  <keyword>non ulcer dyspepsia</keyword>
  <keyword>drug treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

